New: the shifts that come back across the latest research. See what to focus on

Horizon: now

Drug and device makers connect AI across teams

Drug and medical device companies need connected data and shared controls to move AI beyond isolated experiments into everyday work.

In the report's words: “Pharma and MedTech must move from isolated AI pilots to connected workflows with shared data and oversight.”p4

The number that matters

8%p2

Respondents actively implementing company-wide AI plans

Where to focus

  1. 1Connect research and clinical data across systems and partnersp6
  2. 2Automate tracking of relevant regulatory changesp11
  3. 3Set shared controls for AI systems working togetherp13

The details

Who it affects

R&D, regulatory, and AI leaders at pharma and MedTech companies; company size unspecified.p6, p11, p13

What holds them back

  • R&D leaders struggle to move AI beyond pilots because research and clinical data are fragmented across systems and partners.p6
  • Regulatory teams struggle to track relevant rule changes because they manually scan authority websites for weeks per product cycle.p11
  • AI leaders struggle to scale connected AI agents because they lack shared coordination and controls.p13

The numbers

  • 63% of surveyed biopharma R&D leaders lack the data maturity needed to realize AI’s potential.p2
  • Just 8% are actively implementing enterprise AI strategies.p2

What people search for

  • how to scale AI beyond pilots
  • connect lab and clinical data for AI
  • automate pharma regulatory updates
  • track medical device regulation changes
  • manage multiple AI agents
  • monitor AI agents for compliance